Hetero Labs Ltd V announced the FDA approval of ANDA211182 on September 8, 2026, which is expected to broaden market competition and drive price erosion for the generic version of the drug. The transition to a generic format is likely to broaden patient access while simultaneously pressuring revenue streams for the brand manufacturer in this therapeutic class.